Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Mereo BioPharma (MREO) over the last 6 years, with Q3 2025 value amounting to $4.1 million.

  • Mereo BioPharma's Accumulated Expenses rose 1669.03% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 1669.03%. This contributed to the annual value of $4.1 million for FY2024, which is 2553.5% down from last year.
  • Per Mereo BioPharma's latest filing, its Accumulated Expenses stood at $4.1 million for Q3 2025, which was up 1669.03% from $5.0 million recorded in Q2 2025.
  • Mereo BioPharma's 5-year Accumulated Expenses high stood at $6.4 million for Q2 2022, and its period low was $2.5 million during Q1 2024.
  • In the last 5 years, Mereo BioPharma's Accumulated Expenses had a median value of $4.6 million in 2025 and averaged $4.5 million.
  • As far as peak fluctuations go, Mereo BioPharma's Accumulated Expenses surged by 7528.8% in 2021, and later crashed by 2553.5% in 2024.
  • Over the past 5 years, Mereo BioPharma's Accumulated Expenses (Quarter) stood at $5.2 million in 2021, then rose by 5.4% to $5.4 million in 2022, then increased by 0.57% to $5.5 million in 2023, then dropped by 25.54% to $4.1 million in 2024, then grew by 1.15% to $4.1 million in 2025.
  • Its Accumulated Expenses stands at $4.1 million for Q3 2025, versus $5.0 million for Q2 2025 and $2.9 million for Q1 2025.